ClinicalTrials.gg
CompletedNCT03761056ZUMA-12Updated Dec 4, 2024Results posted

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

A Phase 2 interventional study of Axicabtagene Ciloleucel and Fludarabine in B-cell Lymphoma, sponsored by Kite, A Gilead Company. Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 398 studies in Lymphoma, B-Cell with a site in United States — 90 open to participants now, 156 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
167th of 380
42 · median 37
Started
2019
with 21 others
Phase 2
112 of 398
22 open now
Registered
204th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 167th largest by enrollment of the 380 interventional ones that give a count, is one of 22 that started in 2019, is one of 112 in phase 2, and was the 204th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

90 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.

After the end of KTE-C19-112 (ZUMA-12), participants who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.

03

Conditions studied

  • B-cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed large B-cell lymphoma
  • High-grade large B-cell lymphoma
  • Individuals must have a positive interim positron emission tomography (PET) (Deauville PET score of 4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy
  • No evidence, suspicion and/or history of central nervous system (CNS) involvement of lymphoma
  • (ECOG) performance status of 0 or 1
  • ≥ 1000/μL
  • count ≥ 75,000/μL
  • Absolute lymphocyte count ≥ 100/μL
  • Adequate renal, hepatic, pulmonary, and cardiac function defined as:

    • (as estimated by Cockcroft Gault) ≥ 60 mL/min
    • Serum (ALT) and aspartate aminotransferase (AST) ≤ 2.5 (ULN)
    • Total ≤1.5 mg/dL, except in individuals with Gilbert's syndrome
  • Cardiac ≥ 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no (ECG) findings
  • No clinically significant pleural effusion
  • Baseline oxygen saturation > 92% on room air

Key Exclusion Criteria:

  • History of other than nonmelanoma skin cancer or carcinoma in situ (eg cervix, bladder, breast) unless disease free for at least 3 years
  • History of Richter's transformation of chronic lymphocytic leukemia or primary mediastinal B-cell lymphoma
  • History of or allogeneic stem cell transplant
  • Prior CD19-targeted therapy
  • Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy
  • Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management
  • History of (HIV) infection or acute or chronic active or C infection
  • Presence of any indwelling line or drain dedicated central venous access catheters, such as a Port-a-Cath or Hickman catheter, are permitted
  • Individuals with detectable cerebrospinal fluid malignant cells, , or active CNS lymphoma
  • History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any disease with CNS involvement
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
  • History of autoimmune disease resulting in end organ injury or requiring systemic /systemic disease modifying agents within the last 2 years
  • History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Axicabtagene Ciloleucel

    Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered. Participants who achieve partial response or complete response and subsequently experience disease progression will have an option to receive second course of conditioning chemotherapy therapy and axicabtagene ciloleucel. Participants will receive the same axicabtagene ciloleucel regimen as the original target dose anytime during the study.

    Biological: Axicabtagene Ciloleucel · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

    Also known as: Yescarta®

  • Administered according to package insert

  • Administered according to package insert

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators

    CR Rate is the percentage of participants with CR (complete metabolic response (CMR); complete radiological response (CRR)). CMR: positron emission tomography (PET) 5-point scale (5-PS) scores of 1 (no uptake above background), 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass); no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow (BM). CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter of lesion (LDi); no extralymphatic sites of disease; absent non-measured lesion (NMLs); organ enlargement regress to normal; no new sites; and bone marrow normal by morphology.

    Time frame: Up to 4 years

Secondary outcomes

  1. Objective Response Rate (ORR) Per the Lugano Classification as Determined by Study Investigators

    ORR: percentage of participants with CR (CMR;CRR) or PR (partial metabolic response (PMR); partial radiologic response (PRR)). CMR: PET 5PS scores of 1 (no uptake above background, 2 (uptake ≤mediastinum), 3 (uptake \>mediastinum but ≤liver) with/without a residual mass; no new lesions; no evidence of FDG-avid disease in BM. CRR: target nodes/nodal masses regressed to ≤1.5 cm in LDi; no extralymphatic sites of disease; absent NMLs; organ enlargement regress to normal; no new sites; bone marrow morphology normal. PMR: scores 4 (uptake moderately \>liver),5 (uptake markedly \>liver, new lesions) with reduced uptake compared with baseline and residual mass; no new lesions; responding disease at interim/residual disease at end of treatment (EOT). PRR: ≥50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absent/normal, regressed, but no increase of NMLs; spleen regressed by \>50% in length beyond normal; no new sites.

    Time frame: Up to 4 years

  2. Duration of Response (DOR) Per the Lugano Classification

    DOR is defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and is the time from the first objective response to disease progression (PD) (Lugano classification) or death from any cause. Objective response is defined in outcome measure (OM) 2. PD is defined as a score 4 (uptake moderately \> liver) or 5 (uptake markedly \>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. Kaplan-Meier (KM) estimates were used for analysis.

    Time frame: Up to 4 years

  3. Event-Free Survival (EFS)

    EFS was defined as the time from axicabtagene ciloleucel infusion date to earliest date of disease progression (Lugano classification), commencement of subsequent new anti-lymphoma therapy including stem cell transplant, or death from any cause. PD is defined in OM 3. KM estimates were used for analysis.

    Time frame: Up to 4 years

  4. Progression-Free Survival (PFS)

    PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 3. KM estimates were used for analysis.

    Time frame: Up to 4 years

  5. Overall Survival (OS)

    OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any cause. KM estimates were used for analysis.

    Time frame: Up to 4 years

  6. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAE)

    An AE was any untoward medical occurrence in a participant in a clinical trial participant, which did not necessarily have a causal relationship with the treatment. Treatment-emergent adverse events were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion. Serious adverse event was defined as an event that resulted in the following: death; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; and medically important event or reaction.

    Time frame: Up to 2 years

  7. Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value

    Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 2 years

  8. Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Value

    Grading categories were determined by CTCAE version 5.0.

    Time frame: Up to 2 years

  9. Relapse With Central Nervous System (CNS) Disease

    Relapse with CNS disease was defined as the time from the axicabtagene ciloleucel infusion date to the earliest date of CNS involvement with lymphoma as determined by typical symptoms, cerebrospinal fluid (CSF) evaluation, and/or diagnostic imaging.

    Time frame: Up to 4 years

  10. Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood

    Peak was defined as the maximum number of CAR T cells in blood measured after infusion.

    Time frame: Up to Month 24

  11. Peak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8

    Peak is defined as the maximum post-baseline level of cytokine from baseline to Week 4.

    Time frame: Up to Week 4

  12. Peak Serum Level of C-Reactive Protein (CRP)

    Peak is defined as the maximum post-baseline level of cytokine from baseline to Week 4.

    Time frame: Up to Week 4

  13. Peak Serum Level of Ferritin

    Peak is defined as the maximum post-baseline level of cytokine from baseline to Week 4.

    Time frame: Up to Week 4

  14. Time to Peak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8, CRP, and Ferritin

    Time to peak is defined as the number of days from axicabtagene ciloleucel infusion to the date when the cytokine first reached the maximum post-baseline level.

    Time frame: Up to Week 4

07

Results

Posted Jul 8, 2022

Participant flow

Participants were enrolled at study sites in the United States, France, and Australia.

Participant flow — Overall Study
MilestoneAxicabtagene Ciloleucel
Started42
Completed29
Not completed13
Withdrew: Death8
Withdrew: Enrolled but never treated2
Withdrew: Withdrawal of consent from further follow-up2
Withdrew: Investigator decision1

Outcome measures

PrimaryComplete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators

CR Rate is the percentage of participants with CR (complete metabolic response (CMR); complete radiological response (CRR)). CMR: positron emission tomography (PET) 5-point scale (5-PS) scores of 1 (no uptake above background), 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass); no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow (BM). CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter of lesion (LDi); no extralymphatic sites of disease; absent non-measured lesion (NMLs); organ enlargement regress to normal; no new sites; and bone marrow normal by morphology.

Time frame:
Up to 4 years
Reported as:
Number · percentage of participants
Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators
percentage of participantsAxicabtagene Ciloleucel
Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators86 (71 to 95)
SecondaryObjective Response Rate (ORR) Per the Lugano Classification as Determined by Study Investigators

ORR: percentage of participants with CR (CMR;CRR) or PR (partial metabolic response (PMR); partial radiologic response (PRR)). CMR: PET 5PS scores of 1 (no uptake above background, 2 (uptake ≤mediastinum), 3 (uptake \>mediastinum but ≤liver) with/without a residual mass; no new lesions; no evidence of FDG-avid disease in BM. CRR: target nodes/nodal masses regressed to ≤1.5 cm in LDi; no extralymphatic sites of disease; absent NMLs; organ enlargement regress to normal; no new sites; bone marrow morphology normal. PMR: scores 4 (uptake moderately \>liver),5 (uptake markedly \>liver, new lesions) with reduced uptake compared with baseline and residual mass; no new lesions; responding disease at interim/residual disease at end of treatment (EOT). PRR: ≥50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absent/normal, regressed, but no increase of NMLs; spleen regressed by \>50% in length beyond normal; no new sites.

Time frame:
Up to 4 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per the Lugano Classification as Determined by Study Investigators
percentage of participantsAxicabtagene Ciloleucel
Objective Response Rate (ORR) Per the Lugano Classification as Determined by Study Investigators92 (78 to 98)
SecondaryDuration of Response (DOR) Per the Lugano Classification

DOR is defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and is the time from the first objective response to disease progression (PD) (Lugano classification) or death from any cause. Objective response is defined in outcome measure (OM) 2. PD is defined as a score 4 (uptake moderately \> liver) or 5 (uptake markedly \>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. Kaplan-Meier (KM) estimates were used for analysis.

Time frame:
Up to 4 years
Reported as:
Median · months
Duration of Response (DOR) Per the Lugano Classification
monthsAxicabtagene Ciloleucel
Duration of Response (DOR) Per the Lugano ClassificationNA (NA to NA)
SecondaryEvent-Free Survival (EFS)

EFS was defined as the time from axicabtagene ciloleucel infusion date to earliest date of disease progression (Lugano classification), commencement of subsequent new anti-lymphoma therapy including stem cell transplant, or death from any cause. PD is defined in OM 3. KM estimates were used for analysis.

Time frame:
Up to 4 years
Reported as:
Median · months
Event-Free Survival (EFS)
monthsAxicabtagene Ciloleucel
Event-Free Survival (EFS)NA (NA to NA)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 3. KM estimates were used for analysis.

Time frame:
Up to 4 years
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsAxicabtagene Ciloleucel
Progression-Free Survival (PFS)NA (NA to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any cause. KM estimates were used for analysis.

Time frame:
Up to 4 years
Reported as:
Median · months
Overall Survival (OS)
monthsAxicabtagene Ciloleucel
Overall Survival (OS)NA (NA to NA)
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAE)

An AE was any untoward medical occurrence in a participant in a clinical trial participant, which did not necessarily have a causal relationship with the treatment. Treatment-emergent adverse events were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion. Serious adverse event was defined as an event that resulted in the following: death; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; and medically important event or reaction.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAE)
percentage of participantsAxicabtagene Ciloleucel
TEAEs100
Treatment-Emergent SAE55
SecondaryPercentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value

Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value
percentage of participantsAxicabtagene Ciloleucel
Hemoglobin3
Alanine Aminotransferase8
Alkaline Aminotransferase0
Aspartate Aminotransferase5
Bilirubin20
Calcium5
Creatinine5
Glucose15
Magnesium5
Sodium0
Urate18
SecondaryPercentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Value

Grading categories were determined by CTCAE version 5.0.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Value
percentage of participantsAxicabtagene Ciloleucel
Hemoglobin43
Leukocytes93
Lymphocytes75
Neutrophils95
Platelets25
Albumin3
Calcium10
Glucose0
Magnesium3
Potassium5
Sodium23
SecondaryRelapse With Central Nervous System (CNS) Disease

Relapse with CNS disease was defined as the time from the axicabtagene ciloleucel infusion date to the earliest date of CNS involvement with lymphoma as determined by typical symptoms, cerebrospinal fluid (CSF) evaluation, and/or diagnostic imaging.

Time frame:
Up to 4 years
Reported as:
Median · months
Relapse With Central Nervous System (CNS) Disease
monthsAxicabtagene Ciloleucel
Relapse With Central Nervous System (CNS) Disease0 (0 to 0)
SecondaryPharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood

Peak was defined as the maximum number of CAR T cells in blood measured after infusion.

Time frame:
Up to Month 24
Reported as:
Median · cells/µL
Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood
cells/µLAxicabtagene Ciloleucel
Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood36.27 (20.51 to 133.96)
SecondaryPeak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8

Peak is defined as the maximum post-baseline level of cytokine from baseline to Week 4.

Time frame:
Up to Week 4
Reported as:
Median · pg/mL
Peak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8
pg/mLAxicabtagene Ciloleucel
Granzyme B28.5 (11.8 to 75.6)
IFNg409.4 (157.8 to 856.8)
IL-216.4 (9.7 to 32.9)
IL-56.3 (6.3 to 26.2)
IL-635.1 (13.2 to 181.1)
IL-863.0 (30.1 to 107.5)
SecondaryPeak Serum Level of C-Reactive Protein (CRP)

Peak is defined as the maximum post-baseline level of cytokine from baseline to Week 4.

Time frame:
Up to Week 4
Reported as:
Median · mg/L
Peak Serum Level of C-Reactive Protein (CRP)
mg/LAxicabtagene Ciloleucel
Peak Serum Level of C-Reactive Protein (CRP)208.4 (60.9 to 407.5)
SecondaryPeak Serum Level of Ferritin

Peak is defined as the maximum post-baseline level of cytokine from baseline to Week 4.

Time frame:
Up to Week 4
Reported as:
Median · ng/mL
Peak Serum Level of Ferritin
ng/mLAxicabtagene Ciloleucel
Peak Serum Level of Ferritin749.1 (473.9 to 1874.3)
SecondaryTime to Peak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8, CRP, and Ferritin

Time to peak is defined as the number of days from axicabtagene ciloleucel infusion to the date when the cytokine first reached the maximum post-baseline level.

Time frame:
Up to Week 4
Reported as:
Median · days
Time to Peak Serum Level of Granzyme B, Interferon-gamma (IFNg), Interleukin (IL)-2, IL-5, IL-6, IL-8, CRP, and Ferritin
daysAxicabtagene Ciloleucel
Granzyme B8 (8 to 8)
IFNg4 (4 to 8)
IL-24 (4 to 4)
IL-51 (1 to 4)
IL-68 (4 to 8)
IL-88 (4 to 8)
CRP4 (4 to 8)
Ferritin8 (6 to 8)

Adverse events

Collected over All-cause mortality: Up to 4 years; Adverse events: Up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axicabtagene Ciloleucel7/42 (16.7%)22/40 (55%)40/40 (100%)
Retreatment Axicabtagene Ciloleucel1/1 (100%)1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventAxicabtagene CiloleucelRetreatment Axicabtagene Ciloleucel
Pericardial effusionCardiac disorders0/401/1
EncephalopathyNervous system disorders5/400/1
Confusional statePsychiatric disorders4/400/1
PyrexiaGeneral disorders3/400/1
Non-cardiac chest painGeneral disorders2/400/1
Covid-19Infections and infestations2/400/1
Covid-19 pneumoniaInfections and infestations2/400/1
Back painMusculoskeletal and connective tissue disorders2/400/1
AnaemiaBlood and lymphatic system disorders1/400/1
NeutropeniaBlood and lymphatic system disorders1/400/1
Most frequent other events
Showing 10 of 59
Most frequent other events
EventAxicabtagene CiloleucelRetreatment Axicabtagene Ciloleucel
ConstipationGastrointestinal disorders8/401/1
DiarrhoeaGastrointestinal disorders20/401/1
Neutrophil count decreasedInvestigations21/401/1
White blood cell count decreasedInvestigations18/401/1
DehydrationMetabolism and nutrition disorders1/401/1
PyrexiaGeneral disorders39/400/1
HeadacheNervous system disorders28/400/1
NauseaGastrointestinal disorders21/400/1
FatigueGeneral disorders20/400/1
HypotensionVascular disorders14/400/1

Baseline characteristics

Safety Analysis Set included all participants treated with any dose of axicabtagene ciloleucel.

Age, Categorical
Age, Categorical(Participants)Axicabtagene Ciloleucel
<=18 years0
Between 18 and 65 years25
>=65 years15
Age, Continuous
Age, Continuous(years)Axicabtagene Ciloleucel
Mean60.2 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Axicabtagene Ciloleucel
Female13
Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Axicabtagene Ciloleucel
Hispanic or Latino2
Not Hispanic or Latino36
Unknown or Not Reported2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Axicabtagene Ciloleucel
Race — American Indian or Alaska Native1
Race — Asian1
Race — Black or African American1
Race — White33
Race — Other4
Region of Enrollment
Region of Enrollment(Participants)Axicabtagene Ciloleucel
United States32
France2
Australia6
08

Study locations

7 sites
  • Banner Health MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • City of Hope
    Duarte, California 91010-3012, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Hopital Saint Louis
    Paris, 75475, France
09

References and documents

Publications

  • Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. 739 Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL) [Abstract]. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition; 2021 11-14 December.
  • Neelapu SS, Dickinson M, Ulrickson ML, Oluwole OO, Herrera AF, Thieblemont C, et al. 405 Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B-Cell Lymphoma (LBCL) [Abstract]. 62nd American Society of Hematology (ASH) Annual Meeting and Exposition Virtual; 2020 05-08 December.
  • Neelapu SS, Chavez JC, Lin Y, Munoz J, Ujjani CS, Riedell P, et al. ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) as a First-Line Therapy in Patients (Pts) with High-Risk Large B-Cell Lymphoma (LBCL) [Abstract]. J Clin Oncol 2019;37 (15).
  • Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 Apr;28(4):735-742. doi: 10.1038/s41591-022-01731-4. Epub 2022 Mar 21. PubMed 35314842 ↗
  • Chavez JC, Dickinson M, Munoz JL, Ulrickson ML, Thieblemont C, Oluwole OO, et al. 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). Blood 2023;142 (Supplement 1):894-7

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Oct 2023, 56 months.

Of 121 phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 73. This study's 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Dec 3, 2018
StartActual
Jan 29, 2019
Primary completionActual
Oct 12, 2023
CompletionActual
Oct 12, 2023
Results first posted
Jul 8, 2022
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03761056
Responsible party
Sponsor
First posted
Dec 3, 2018
Start date
Jan 29, 2019
Primary completion
Oct 12, 2023
Completion
Oct 12, 2023
Results posted
Jul 8, 2022
Last update
Dec 4, 2024

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axicabtagene ciloleucel

Start the discussion